If you or someone you love has been diagnosed with NMOSD, you have likely already learned how fast this disease can take vision and mobility, and how different it is from multiple sclerosis even though the two are constantly confused. This page is a deep, honest walk through what NMOSD actually is at the cellular level, why the distinction from MS is not academic but a matter of safety, and the specific, named mechanisms where sea moss's minerals and bioactives may support the disease terrain. We will be equally clear, and repeatedly so, about everything sea moss cannot do and the medications it must never replace. The whole point is honesty about limits.

1. What Is Neuromyelitis Optica Spectrum Disorder?

Neuromyelitis optica spectrum disorder is a chronic, relapsing autoimmune disease of the central nervous system that preferentially attacks the optic nerves and spinal cord, and in many people the brainstem and certain deep brain regions as well. Historically called Devic's disease, it was long mistaken for a severe variant of multiple sclerosis. The discovery of a specific antibody in 2004 reframed it as an entirely distinct disease with its own mechanism, prognosis, and treatment rules.

The defining biological feature of NMOSD is that it is an astrocytopathy, not primarily a demyelinating disease. Astrocytes are the star-shaped support cells of the CNS that maintain the blood-brain barrier, buffer ions and water, recycle neurotransmitters, and nourish neurons and oligodendrocytes. In NMOSD, the immune attack is aimed first at astrocytes. The loss of myelin that follows is a downstream, bystander consequence of astrocyte destruction, the opposite causal order from MS, where myelin and the oligodendrocytes that make it are the primary targets and astrocytes are relatively spared.

That single distinction, primary astrocyte injury versus primary myelin injury, explains nearly everything that follows on this page: why NMOSD attacks are so severe, why the antibody test matters so much, and why drugs designed for MS can be useless or even harmful in NMOSD. Across its 92 minerals, sea moss may offer nutritional support for the broader terrain in which this disease operates, never a way to alter that disease mechanism.

2. The AQP4 Antibody and Astrocyte Targeting

The molecular heart of NMOSD is aquaporin-4 (AQP4), the most abundant water channel in the central nervous system. AQP4 is concentrated on the end-feet of astrocytes, the specialized processes that wrap around brain blood vessels to form part of the blood-brain barrier, and on astrocyte membranes lining the ependyma around the brain's ventricles and central canal. These are precisely the locations where NMOSD lesions form.

In roughly 70 to 80 percent of people with NMOSD, the blood contains an IgG autoantibody directed against AQP4, the AQP4-IgG (also called NMO-IgG). These are termed AQP4-IgG seropositive patients. The antibody is highly specific to NMOSD; finding it essentially confirms the diagnosis and, importantly, distinguishes the disease from MS, in which AQP4-IgG is absent.

The complement-mediated destruction cascade

Understanding how AQP4-IgG damages tissue is essential, because it is exactly where several sea moss mechanisms become relevant. The cascade runs roughly like this:

• Antibody binding: AQP4-IgG (predominantly the IgG1 subclass) binds AQP4 on astrocyte end-feet.
• Complement activation: bound IgG1 recruits C1q, the trigger of the classical complement pathway. This sets off the cascade through C3 and C5.
• Membrane attack complex (MAC): the cascade culminates in the C5b-9 membrane attack complex, which punches pores in the astrocyte membrane and causes astrocyte death.
• Bystander injury: dying astrocytes can no longer support neighboring cells. Oligodendrocytes are injured secondarily, producing demyelination from the "outside-in," the reverse of the MS sequence.
• Inflammatory amplification: the attack recruits neutrophils and eosinophils (cell types largely absent from MS lesions) and is driven by cytokines including IL-6, IL-17, and GM-CSF.

This complement-and-cytokine cascade is the engine of NMOSD tissue damage. It is also the reason the FDA-approved preventive drugs target complement (eculizumab), the antibody-producing B-cells (inebilizumab), or IL-6 signaling (satralizumab). When we discuss fucoidan, selenium, zinc, and omega-3 below, the relevant question is always whether a nutrient plausibly touches a step in this cascade, not whether it replaces these drugs. It does not.

3. NMOSD vs Multiple Sclerosis: A Critical Distinction

NMOSD and MS look superficially similar, both cause optic neuritis, both cause spinal cord symptoms, both relapse. But they are different diseases with different mechanisms, prognoses, and, most importantly, different correct treatments. Getting the distinction wrong is not a minor error; it can lead to severe harm, because some MS drugs actively worsen NMOSD (covered in detail in Section 9).

A few points deserve emphasis. NMOSD attacks tend to be more destructive and less recoverable than MS attacks; disability accumulates with each relapse rather than smoldering progressively the way primary progressive MS (PPMS) does. The presence of longitudinally extensive transverse myelitis (LETM), a spinal cord lesion spanning three or more vertebral segments, strongly suggests NMOSD over MS, where cord lesions are short. And an area postrema lesion in the dorsal medulla is considered essentially pathognomonic for NMOSD. These distinctions are why NMOSD must be confirmed, ideally with AQP4-IgG testing, before any preventive therapy is chosen.

4. Clinical Attacks and the 2015 Diagnostic Criteria

NMOSD presents through a defined set of core clinical syndromes, and recognizing them is what gets people to the right antibody test and the right treatment. The six core characteristics are:

• Optic neuritis: inflammation of the optic nerve causing eye pain and vision loss, in NMOSD often bilateral and severe, with worse visual outcomes than typical MS optic neuritis.
• Acute myelitis: spinal cord inflammation, characteristically longitudinally extensive (LETM, ≥3 segments), producing weakness, sensory loss, and bladder/bowel dysfunction.
• Area postrema syndrome: intractable nausea, vomiting, or hiccups from a lesion in the area postrema of the dorsal medulla - frequently the first symptom and frequently misdiagnosed as a gastrointestinal problem (see Section 12).
• Acute brainstem syndrome: double vision, vertigo, facial sensory changes, or other cranial-nerve signs.
• Acute diencephalic syndrome: from lesions around the hypothalamus and thalamus, sometimes causing sleep, temperature, or hormonal disturbances.
• Cerebral syndrome: from large or atypical brain lesions, often in AQP4-rich regions.

The 2015 IPND diagnostic criteria

The 2015 International Panel for NMO Diagnosis (IPND) criteria formalized how NMOSD is diagnosed, splitting it by antibody status:

• AQP4-IgG seropositive: diagnosis requires at least one core clinical characteristic plus a positive AQP4-IgG test (by a reliable assay, ideally cell-based), with exclusion of alternative diagnoses.
• AQP4-IgG seronegative or unknown status: a stricter bar applies, requiring at least two core clinical characteristics from one or more attacks, at least one of which must be optic neuritis, LETM, or area postrema syndrome, plus additional MRI requirements and exclusion of other diagnoses.

This two-tier structure exists because the antibody is so specific that finding it lowers the clinical bar, while its absence demands more clinical and imaging evidence before NMOSD can be confidently diagnosed. None of this is something sea moss has any role in; it is medical diagnosis, full stop. But understanding it explains why the AQP4 antibody test is the pivot point of the whole disease.

5. Fucoidan: Complement, NF-kB, IL-6 and Barrier Support

Of all the bioactives in sea moss, fucoidan, the sulfated polysaccharide concentrated in this seaweed, is the most mechanistically interesting for NMOSD, because several of its documented activities map onto the exact cascade described in Section 2. To be clear up front: these are preclinical, cell-and-animal mechanisms, not human NMOSD trial results. They describe why fucoidan may support the surrounding terrain, never proof that it does anything in NMOSD patients.

NF-kB suppression in astrocytes and endothelium

NF-kB is the master switch for inflammatory gene expression. In NMOSD, activation of NF-kB in astrocytes and in the endothelial cells of the blood-brain barrier drives the production of cytokines (including IL-6) and adhesion molecules that recruit the neutrophils and eosinophils seen in lesions. Fucoidan has been shown in preclinical models to downregulate NF-kB signaling, a plausible anti-inflammatory touchpoint relevant to the astrocyte and endothelial inflammation of NMOSD.

Complement inhibition - directly relevant to the MAC

This is the most striking overlap. Sulfated polysaccharides like fucoidan have been studied for complement-inhibitory activity, including binding to C1q (the trigger of the classical pathway that AQP4-IgG activates) and dampening the alternative complement pathway. Because the C1q-to-C5b-9 MAC cascade is the direct executioner of astrocytes in NMOSD, and because the lead approved drug (eculizumab) works by blocking complement at C5, fucoidan's complement-modulating profile is a genuinely relevant, if far weaker and unproven, mechanistic parallel. We are not claiming fucoidan blocks complement in NMOSD patients; we are noting that the pathway it touches in the lab is the same pathway that destroys astrocytes.

IL-6 reduction

IL-6 trans-signaling is a central driver of NMOSD pathology: it promotes survival of the plasmablasts that produce AQP4-IgG, weakens the blood-brain barrier, and amplifies inflammation. IL-6 receptor blockade is exactly how the approved drug satralizumab works. Fucoidan has been associated with reduced IL-6 in preclinical inflammation models, again a plausible directional overlap with NMOSD biology, not a treatment-strength effect.

BAFF / APRIL modulation

The antibody-producing B-cells behind AQP4-IgG depend on survival factors BAFF and APRIL. Some preclinical data suggest fucoidan can modulate BAFF/APRIL signaling, which would in theory temper the B-cell compartment that generates the pathogenic anti-AQP4 antibody. This is highly speculative for NMOSD specifically and should be read as a mechanistic curiosity, not a claim.

Blood-brain barrier protection

For AQP4-IgG to reach AQP4 on astrocyte end-feet, it must cross or exploit a compromised blood-brain barrier. Fucoidan has shown endothelial-protective effects in models, including support for tight junction proteins such as ZO-1 and claudin-5. A better-sealed barrier would, in principle, limit antibody access to its target on the end-feet. Once more: plausible mechanism, not demonstrated NMOSD benefit.

Antiviral activity

Some hypotheses propose viral triggers in autoimmune CNS disease. Fucoidan has recognized antiviral properties in laboratory models because its structure mimics heparan sulfate, a viral attachment molecule. This is mentioned only for completeness and is relevant only if a viral trigger is hypothesized; there is no established viral cause of NMOSD that sea moss addresses.

6. Selenium: Selenoproteins and Astrocyte Protection

Selenium is the essential cofactor for a family of selenoproteins that defend cells against oxidative damage, and several of them are concentrated in exactly the tissues NMOSD attacks. This makes selenium one of the more directly relevant minerals in sea moss for the NMOSD terrain.

Selenoprotein P in brain and spinal cord

Selenoprotein P (SELENOP) is the body's main selenium-transport protein, and its expression is highest in the brain and spinal cord, the AQP4-expressing regions where NMOSD lesions form. SELENOP supplies selenium to neural tissue and has antioxidant functions there. Adequate selenium status supports this neural selenoprotein supply chain in the very regions NMOSD targets.

GPx4 and protection from ferroptosis

Glutathione peroxidase 4 (GPx4) is the only enzyme that directly neutralizes lipid peroxides in cell membranes and is the central guardian against ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation. Astrocyte loss is the core lesion of NMOSD, and oxidative and lipid-peroxidation stress accompany the complement attack. By supporting GPx4 activity, adequate selenium may help defend astrocytes (and neighboring cells) against the lipid-peroxidation injury that compounds the primary antibody-and-complement damage.

Thioredoxin reductase and complement-generated oxidative stress

The complement attack and the recruited neutrophils and eosinophils generate substantial reactive oxygen species. Thioredoxin reductase 1 (TrxR1), a selenoenzyme, helps maintain cellular redox balance and reduce this complement-generated oxidative burden. Likewise, GPx1 and GPx2 operate in spinal cord astrocytes and oligodendrocytes, supporting the antioxidant defenses of the very cells injured in NMOSD myelitis.

Selenium has also been studied in the broader context of neurological recovery, where adequate status supports the antioxidant machinery that helps tissue weather and recover from inflammatory insults. The supportive case for NMOSD is straightforward: selenium feeds the selenoprotein antioxidant defenses that astrocytes and spinal cord cells rely on. That is nutritional terrain, not disease modification, and it does not stop the antibody attack.

7. Omega-3 EPA/DHA: Protectins, Resolvins and the Visual Pathway

Omega-3 fatty acids, especially EPA and DHA, are precursors to a remarkable class of lipid mediators that resolve inflammation and protect neural tissue, and they have specific relevance to the optic nerve and spinal cord that NMOSD targets.

Neuroprotectin D1 - an astrocyte-protective mediator

DHA is the precursor of Neuroprotectin D1 (NPD1, also called protectin D1 or PD1), one of the most potent astrocyte-protective lipid mediators known. In preclinical work, DHA-derived NPD1 promotes astrocyte survival and reduces inflammatory cytokine expression. Because astrocyte death is the central event in NMOSD, a mediator that supports astrocyte survival is mechanistically compelling as a supportive angle, with the usual caveat that this is preclinical biology, not NMOSD trial data.

EPA-derived resolvins and complement

EPA gives rise to resolvins, specialized pro-resolving mediators that actively switch off inflammation. Resolvins have been associated with reduced complement activation and dampened neutrophil-driven inflammation, both of which feature heavily in NMOSD lesions. This positions adequate omega-3 status as supportive of a more resolution-oriented inflammatory tone.

Membrane fluidity at astrocyte end-feet

DHA is a major structural component of neural membranes and supports membrane fluidity, including in the astrocyte end-feet where AQP4 is concentrated. Healthy membrane composition is part of the broad nutritional terrain for astrocyte function.

The visual pathway and spinal cord

DHA is the single most enriched fatty acid in retinal photoreceptors and is critical for optic nerve myelination and visual-pathway integrity. Given how central and often severe optic neuritis is in NMOSD, the visual-pathway role of DHA is particularly relevant to the nutritional support picture. EPA and DHA have likewise been studied in the context of spinal cord recovery, where pro-resolving and membrane-supportive roles may aid the terrain in which recovery occurs. None of this repairs an NMOSD lesion; it is membrane and resolution support, not optic-nerve or cord repair.

Sea moss provides alpha-linolenic acid (ALA), the plant omega-3 precursor, which the body partially converts to EPA and DHA. Because that conversion is limited in humans, people specifically seeking higher EPA/DHA usually combine dietary or supplemental marine sources rather than rely on sea moss alone; sea moss contributes to the omega-3 pool as part of its broad profile.

8. Zinc: Tregs, AQP Function, Astrocyte Homeostasis and MAC

Zinc is an underappreciated mineral with several plausible touchpoints in NMOSD biology, spanning immune regulation, water-channel function, astrocyte buffering, and complement.

FOXP3+ regulatory T-cell induction

Zinc supports the induction and function of FOXP3+ regulatory T-cells (Tregs), the immune cells that keep autoreactivity in check. In NMOSD, robust Treg activity could in principle help reduce activation of the anti-AQP4 B-cell response. Adequate zinc is part of the nutritional support for a balanced regulatory immune compartment, though this is general immunology rather than an NMOSD-specific proven effect.

Zinc and aquaporin water-channel function

Interestingly, zinc modulates aquaporin channel activity, and AQP4 is the central molecule of NMOSD. Zinc's role in normal water-channel regulation places it within the relevant molecular neighborhood, though the implications for NMOSD specifically remain a matter of basic biology rather than clinical evidence.

Astrocyte homeostasis and metallothionein

Astrocytes use metallothionein proteins to buffer zinc and protect against metal-driven oxidative stress. Healthy astrocyte zinc homeostasis supports the resilience of the very cells NMOSD attacks. Zinc availability feeds this buffering system.

Zinc and the membrane attack complex

There is preclinical interest in zinc's capacity to inhibit the C5b-9 membrane attack complex, the final effector that kills astrocytes in NMOSD. Any modulation of MAC formation is directly relevant to the disease mechanism, though as with the other mechanisms here, this is laboratory biology, not a demonstrated NMOSD treatment effect.

Zinc and visual-pathway recovery

Zinc is concentrated in the retina and is important for normal visual function, making it relevant to the visual-pathway recovery that matters so much after NMOSD optic neuritis. Sea moss contributes zinc within its 92-mineral profile as supportive nutritional terrain across these angles, a supporting role only, never a mechanism that reverses an antibody-driven attack.

9. CRITICAL SAFETY: Several MS Drugs Can Worsen NMOSD

Because NMOSD and MS share symptoms, an NMOSD patient misdiagnosed with MS may be prescribed MS therapies that are wrong for the disease mechanism. Specifically:

• Natalizumab: highly effective in relapsing MS, but reported to worsen NMOSD - it does not address the complement-and-antibody mechanism and has been associated with severe attacks in NMOSD patients.
• Fingolimod (and related S1P modulators): used in MS, but reported to be associated with worsening or severe relapses in NMOSD.
• Interferon-beta: a standard older MS therapy, but it can exacerbate NMOSD and increase attack frequency.

The mechanistic reason is that these drugs are tuned to the T-cell-driven, myelin-targeted biology of MS, not the antibody-and-complement, astrocyte-targeted biology of NMOSD. Giving an NMOSD patient an MS drug can leave the true disease unchecked or stir it up. This is the clearest possible illustration of why NMOSD is its own disease and why strong physician coordination and correct diagnosis come first. Sea moss has no role in this decision whatsoever; it is purely a nutritional consideration to discuss with the neurologist after a correct diagnosis and treatment plan are in place.

10. NMOSD Treatment: Acute Attacks and FDA-Approved Prevention

NMOSD treatment has two arms: stopping acute attacks quickly to limit damage, and preventing future attacks. No food or supplement, including sea moss, belongs in either arm; this section exists so the supportive role of sea moss is understood against the backdrop of what actually controls the disease.

Acute attack treatment

• High-dose IV methylprednisolone: first-line treatment for an acute NMOSD relapse, given to rapidly reduce inflammation.
• Plasma exchange (PLEX): used for severe attacks or attacks not responding adequately to steroids; it physically removes circulating AQP4-IgG antibodies and complement components from the blood. Early plasma exchange is associated with better recovery in severe attacks.

FDA-approved preventive therapies

Modern NMOSD prevention is built on drugs that target the disease mechanism directly:

• Eculizumab: a C5 complement inhibitor that blocks formation of the C5b-9 membrane attack complex - shutting down the final astrocyte-killing step of the cascade.
• Inebilizumab: an anti-CD19 B-cell-depleting antibody that removes the B-cells and plasmablasts producing AQP4-IgG.
• Satralizumab: an anti-IL-6 receptor antibody that blocks the IL-6 signaling central to NMOSD pathology and antibody production.
• Ublituximab: a B-cell-depleting (anti-CD20) antibody used in this class of conditions.

Older preventive options

• Rituximab: an anti-CD20 B-cell-depleting antibody, long used off-label and still widely employed for NMOSD prevention.
• Azathioprine and mycophenolate mofetil (MMF): broad immunosuppressants used as preventive therapy, often when newer biologics are not accessible.

These therapies are proven to reduce NMOSD relapses, the outcome that protects vision and mobility. What sea moss cannot do: it cannot block C5 or the membrane attack complex, cannot deplete AQP4-IgG-producing B-cells, cannot block IL-6 receptors, cannot halt an acute attack, and cannot modify the disease course. Those are the jobs of the medications above and of your neurologist. Sea moss's contribution is upstream nutritional terrain, and only that.

11. MOGAD vs AQP4-IgG NMOSD

About 30 percent of people who look clinically like NMOSD are AQP4-IgG seronegative. A meaningful share of these carry a different antibody, against myelin oligodendrocyte glycoprotein (MOG), and are now recognized as having a separate disease entity: MOG-antibody associated disease (MOGAD).

MOGAD is distinct from AQP4-IgG NMOSD in important ways:

• Different target: MOGAD antibodies target MOG, a myelin/oligodendrocyte surface protein, rather than the AQP4 astrocyte water channel.
• Different complement involvement: the severe complement-mediated astrocyte destruction so characteristic of AQP4-IgG NMOSD is not the same in MOGAD, which generally lacks the severe astrocyte loss.
• Generally better prognosis: MOGAD attacks, including optic neuritis, tend to recover more completely than AQP4-IgG NMOSD attacks, and some MOGAD courses are monophasic rather than relentlessly relapsing.
• Different treatment implications: while there is overlap in attack management, preventive strategies and long-term outlook differ, which is one more reason precise antibody testing matters.

For the purposes of this page, the takeaway is that "NMOSD" is not one uniform thing: AQP4-IgG seropositive disease, AQP4-IgG seronegative disease, and MOGAD have different biology, prognosis, and management. Sea moss's nutritional terrain (antioxidant, anti-inflammatory, membrane-supportive) is broadly relevant across inflammatory CNS conditions, but it is never a substitute for getting the antibody status and diagnosis right with a specialist.

12. Area Postrema Syndrome: The Misdiagnosed Presentation

Area postrema syndrome deserves its own section because it is both characteristic of NMOSD and frequently missed. The area postrema is a small region in the dorsal medulla that lacks a normal blood-brain barrier and is rich in AQP4-expressing astrocytes, making it a favored NMOSD target.

A lesion here produces intractable nausea, vomiting, and hiccups that can persist for days or weeks. Because these are gastrointestinal-sounding symptoms, patients are often worked up for stomach problems, reflux, or psychiatric causes, and may undergo extensive GI evaluation before anyone considers a neurological cause. Yet area postrema syndrome can be the very first manifestation of NMOSD, sometimes preceding optic neuritis or myelitis, which is exactly why it is so often misdiagnosed.

Recognizing unexplained, persistent nausea, vomiting, or hiccups as a possible NMOSD presentation, and pursuing brain MRI and AQP4-IgG testing, can dramatically shorten time to diagnosis and treatment. This is purely a medical recognition point. The relevance to sea moss is indirect at best: persistent vomiting can impair nutrition and hydration, and once the syndrome is medically controlled, a well-nourished recovery terrain matters, but sea moss neither diagnoses nor treats area postrema syndrome, which is a neurological emergency requiring urgent specialist care.

13. Visual Recovery, Mobility and Quality of Life

Because NMOSD attacks are so destructive, the disease's burden falls heavily on vision and mobility, and on the quality of life those determine. Preserving function is the central goal of care, achieved primarily through preventing relapses with the medications discussed earlier.

Visual recovery and optic nerve rehabilitation

NMOSD optic neuritis tends to cause more profound vision loss and poorer spontaneous recovery than MS optic neuritis, which is why prompt acute treatment (steroids, and plasma exchange for severe attacks) matters so much. Beyond acute treatment, low-vision rehabilitation, visual aids, and occupational therapy help people adapt and maximize remaining function. The nutritional angle here is modest and supportive: DHA's enrichment in retinal photoreceptors and the optic nerve, and zinc's role in retinal function, are part of the broad nutritional terrain for visual-pathway health, never a treatment that restores lost vision.

Mobility preservation

LETM can cause significant weakness, sensory loss, and bladder/bowel dysfunction. Physical therapy, mobility aids, spasticity management, and bladder care are central to preserving independence. Again, the best protection of mobility is relapse prevention; nutritional support sits alongside, not instead of, that medical strategy.

Quality of life

Living with a relapsing disease that can take vision and mobility carries real psychological weight, and fatigue, pain, and mood symptoms are common. Comprehensive NMOSD care addresses these directly. A consistent, well-nourished daily routine, of which sea moss can be one small, conservative part in coordination with the care team, may support the broader sense of doing something constructive for one's health terrain, with realistic expectations about what nutrition can and cannot do.

14. How to Use Sea Moss for NMOSD Nutritional Support

If, in coordination with your neurologist, you choose to use sea moss as nutritional support alongside your NMOSD treatment, here is a sensible, conservative approach.

• Dose: 1 to 2 tablespoons of sea moss gel daily, taken consistently. More is not better, particularly given the iodine and selenium content.
• Timing: take with a meal containing some fat, since omega-3 precursors and several cofactors absorb better alongside dietary fat.
• Monitor selenium and iodine carefully: both have narrow safe ranges. Avoid stacking sea moss with additional high-dose selenium or iodine supplements unless your provider has specifically advised it, and be especially cautious if you have any coexisting thyroid condition (see the iodine and thyroid note below).
• Account for medication interactions: fucoidan has mild anticoagulant properties, and minerals can interact with various medications. NMOSD patients are often on immunosuppressants or biologics; review sea moss with the team managing those therapies before starting.
• Coordinate strongly with your neurologist: NMOSD is severely disabling and demands close specialist management. Bring sea moss into your care plan openly so your team can watch for interactions and interpret labs correctly. Never let any supplement delay, reduce, or replace prescribed therapy.
• Set realistic expectations: nutritional support is cumulative and slow. Judge it over months, never as a measure of disease control. NMOSD activity is tracked by your neurologist through clinical assessment, MRI, and antibody status, not by how a supplement makes you feel.

Iodine and thyroid note

NMOSD has a documented overlap with autoimmune thyroid disease, including Hashimoto's thyroiditis, and a subset of NMOSD patients have elevated thyroid peroxidase antibodies. Sea moss is iodine-rich, and iodine intake must be approached carefully in anyone with thyroid autoimmunity, because both too little and too much iodine can disrupt thyroid function, and excess iodine can be especially problematic in autoimmune thyroid disease. Iodine tolerability is an individual matter to monitor. If you have any thyroid condition or thyroid antibodies, coordinate sea moss use with the provider managing your thyroid as well as your neurologist.

With 92 minerals in one wildcrafted ingredient, sea moss gel can be a simple daily anchor for the nutritional side of an NMOSD-support routine, layered onto, and firmly subordinate to, the medical care that does the real work.

15. Frequently Asked Questions